Skip to content
MarketScale
‹ Back to IndustriesSciences

What the Future Looks Like if We Get It Right

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Ai in HealthcareAmbient MonitoringArtificial IntelligenceClinician Workflow
Share

Key takeaways

01

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities.

02

This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right.

03

Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical Informatics Corp., with a special appearance from Bikram Day, Director of Informatics at Medical Informatics Corp., to explore bold predictions, personalized care, and the safeguards needed to responsibly build the future of healthcare.

Yellapantula grounds the conversation in real-world innovation, sharing projects that use physiological data to predict cardiac arrest, compare CPR techniques, and detect critical events through signal analysis alone. These experiences shape her vision for the future, where predictive analytics are deeply personalized. “All our predictive analytics should be personalized to us,” she explains. “Your history, your genetics, your past surgeries—really fine-tuning your model to you.”

Looking toward 2050, the episode imagines a healthcare system that is proactive rather than reactive. Yellapantula envisions universal monitoring on hospital entry, where wearables immediately screen for major events like strokes or heart attacks, and monitoring intensity adapts based on patient acuity. “You’re customizing your monitoring and producing the best prediction to be sent to the correct people,” she says, emphasizing the need to surface only the most relevant, actionable alerts without overwhelming clinicians.

The discussion also explores how clinician workflows could change. Instead of searching across fragmented systems, nurses and physicians would receive a comprehensive, centralized view of each patient’s physical, emotional, and psychological state. “Those logistical hassles should really be in the past,” Yellapantula notes. “We’ve gone to outer space. We can bring our healthcare system up to speed.”

Day expands the vision further, pointing to advances in wearable technology, biomarker detection, and multimodal AI. He predicts that future wearables will not only collect data but process it intelligently, flagging early warning signs and guiding patients toward timely intervention. “The cost to intervene is going to go down,” he says, making proactive care more accessible and equitable.

But with opportunity comes responsibility. One of the episode’s most critical lessons centers on data integrity. Yellapantula warns that poorly managed training data can undermine even the best AI models. “To build a good predictive model, you need good quality data and good quality labels,” she explains, urging the industry to address data contamination now before it becomes a limiting factor.

The episode closes with a clear takeaway: if patient monitoring succeeds, it enables earlier detection, smarter decisions, and more personalized care. “We’re able to have very actionable alerts where we really have the greatest impact on patient outcomes,” Yellapantula says. It’s a future built not just on better technology, but on better choices, collaboration, and trust.

Connect with the thought leaders driving this discussion:

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Internet of Things Group.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.